Table 2 Median survival according to clinical, radiological or biochemical response

From: Peptide receptor radionuclide therapy with 90Y-DOTATATE/90Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity

Responses

Number (%)

Median survival in months (95% CI)

Radiological response

Progressive disease

14/49 (28.5)

18 (10, −)

Stable disease

23/49 (47)

56 (34, −)

Positive response

12/49 (24.5)

51 (34, −)

Biochemical response

Progressive disease

11/35 (31)

35 (18, −)

Stable disease

16/35 (46)

56 (46, −)

Positive response

8/35 (23)

34 (19, −)

Clinical response

Progressive disease

8/57 (14)

11 (4, −)

Stable disease

21/57 (37)

56 (23, −)

Positive response

28/57 (49)

47 (35, −)

No. outcomes in which a response was achieved

One

16/57 (28)

32 (18, 46)

Two

21/57 (37)

57 (23, −)

Three

17/57 (30)

56 (43, −)

  1. Abbreviation: CI=confidence interval.